National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Ventilator-associated pneumonia (VAP) is an important nosocomial infection in mechanically ventilated patients at intensive care unit (ICU). The administration of accurate and timely initial empirical antibiotic therapy is essential to reduce the morbidity and mortality from Ventilator-associated pneumonia. Initial empiric antimicrobial therapy for VAP greatly depends on the type of causative pathogen and its resistance pattern. During the six months study period, 196 patients received mechanical ventilation. Endo tracheal aspirates were collected from 22 mechanically ventilated patients with suspected ventilator associated pneumonia. 19 organisms were isolated. All Cefoxitin resistant isolates were studied for the presence of plasmid mediated AmpC beta-lactamase enzyme by Inhibitor disk based method and inducible AmpC beta-lactamase production by Ceftazidime-imipenem antagonism test (CIAT).ESBL production in the gram negative isolates was detected by Phenotypic Confirmatory Test. Incidence rate of VAP was 9.7%. Klebsiella pneumoniae (26%) was the most common organism followed by Pseudomonas aeruginosa (21%) and Acinetobacter spp (16%). (53%) of Gram negative isolates were positive for ESBL production. (6%) was positive for plasmid mediated Amp C beta lactamase production and (6%) was positive for inducible Amp C beta lactamase production. Due to the increasing incidence of drug-resistant organisms, VAP requires an early diagnosis and appropriate antibiotic treatment, to prevent mortality and morbidity. Hence, knowing the bacterial isolates and their antibiotic resistance pattern is essential to improve the clinical outcome of VAP.
Citations |
 |
 |
 |
 |
